NEONC Technologies Secures $10M to Pioneer Intranasal Cancer Therapy Innovations

NEONC Technologies, Inc. (NTI), an early-stage cancer biotechnology company, is excited to announce the successful raise of $10,000,000 in its latest funding round. This significant investment underscores the confidence of our partners and investors in our pioneering approach to cancer treatment. At NTI, we focus on innovative intranasal delivery and other non-traditional methods to administer a novel, highly purified form of monoterpenes—oils derived from fruits and plants—that have shown great promise either as standalone agents or in combination with conventional chemotherapeutic compounds. Our breakthrough approach leverages the unique properties of these monoterpenes to enhance drug delivery and efficacy, particularly when administered through the nasal passage, which may offer improved treatment outcomes compared to traditional methods. The newly raised funds will be strategically deployed to expand our research and development initiatives, including the refinement of our intranasal formulations and the exploration of synergistic effects with established chemotherapeutic agents. Additionally, the capital infusion will support crucial preclinical and early-stage clinical trials aimed at rigorously evaluating the safety and efficacy of our novel therapies. By accelerating our research pipeline, we are positioning NTI at the forefront of innovative therapeutic strategies in oncology, while also opening new avenues for collaboration with academic institutions and industry leaders in the cancer treatment landscape. This funding milestone reinforces our commitment to transforming cancer care, ultimately striving to deliver safer, more effective treatment options for patients worldwide. We are profoundly grateful for the trust placed in us and look forward to pioneering the next wave of cancer therapeutics.